{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+monotherapy&page=2", "query": { "intervention": "placebo monotherapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 429, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+monotherapy&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+monotherapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T16:29:35.875Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02796677", "title": "AMPLIFY - D6571C00001 Duaklir USA Phase III Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)", "type": "DRUG" }, { "name": "Aclidinium bromide 400 μg (AB 400 μg)", "type": "DRUG" }, { "name": "Formoterol fumarate 12 μg (FF 12 μg)", "type": "DRUG" }, { "name": "Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg", "type": "OTHER" }, { "name": "Tiotropium 18 μg (TIO 18 μg)", "type": "DRUG" }, { "name": "Placebo to TIO 18 μg", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "40 Years to 130 Years" }, "enrollment_count": 1595, "start_date": "2016-07-05", "completion_date": "2017-06-08", "has_results": true, "last_update_posted_date": "2018-11-09", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 85, "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more", "locations": [ { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02796677" }, { "nct_id": "NCT03477175", "title": "Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "E7080", "type": "DRUG" }, { "name": "Comparator Drug", "type": "DRUG" }, { "name": "Comparator Drug: Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-08-16", "completion_date": "2023-12-21", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 3, "location_summary": "Torrance, California • Chicago, Illinois • Detroit, Michigan", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03477175" }, { "nct_id": "NCT01147809", "title": "Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombocytopaenia" ], "interventions": [ { "name": "Eltrombopag olamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2010-06", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 33, "location_summary": "Sedona, Arizona • Hot Springs, Arkansas • Rancho Cucamonga, California + 29 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147809" }, { "nct_id": "NCT02028884", "title": "Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuromyelitis Optica (NMO)", "NMO Spectrum Disorder (NMOSD)" ], "interventions": [ { "name": "Satralizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Baseline Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "12 Years to 74 Years" }, "enrollment_count": 85, "start_date": "2014-02-20", "completion_date": "2021-12-23", "has_results": true, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02028884" }, { "nct_id": "NCT01128621", "title": "A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "GSK1292263", "type": "DRUG" }, { "name": "GSK1292263 matching placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 66, "start_date": "2009-11-23", "completion_date": "2010-04-12", "has_results": true, "last_update_posted_date": "2017-10-16", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 2, "location_summary": "Chula Vista, California • Miami, Florida", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01128621" }, { "nct_id": "NCT00195663", "title": "Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Adalimumab placebo", "type": "BIOLOGICAL" }, { "name": "Methotrexate placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 799, "start_date": "2000-12", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-07-12", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 31, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00195663" }, { "nct_id": "NCT01111552", "title": "Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder (MDD)" ], "interventions": [ { "name": "Escitalopram", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 237, "start_date": "2010-07-29", "completion_date": "2011-09-27", "has_results": true, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Carson", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Imperial", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111552" }, { "nct_id": "NCT00943826", "title": "A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 921, "start_date": "2009-06-29", "completion_date": "2015-09-09", "has_results": true, "last_update_posted_date": "2017-09-25", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00943826" }, { "nct_id": "NCT00942188", "title": "A Study of LY2189102 in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "LY2189102", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "20 Years to 75 Years" }, "enrollment_count": 106, "start_date": "2009-06", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 18, "location_summary": "Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00942188" }, { "nct_id": "NCT00690456", "title": "Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Rimonabant", "type": "DRUG" }, { "name": "Placebo (for Rimonabant)", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 403, "start_date": "2008-05", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2016-05-18", "last_synced_at": "2026-09-30T16:29:35.875Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00690456" } ] }